Posters
« Back
Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies
EP25778
Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies
Submitted on 15 May 2017

Pete Stecha, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
Poster Views: 974
View poster »
Poster Abstract
Immunotherapy aims to boost a patient’s own immune system to fight disease. In recent years, a variety of immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of cancer and autoimmune disease.

Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.

Specifically, we developed two bioluminescent reporter-based bioassays to measure T cell activation via CD3 (NFAT-RE) or CD3 + CD28 (IL-2 promoter). These

Corresponding author: richard.somberg@promega.comReport abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


www.thebraindomain.org: Science Writing for Public Engagement
Bartley, O.; Rienecker, K.; Stickland, R.; Pass, R.; Bunga, A.; Cross, E.; & Fagg, J.

Quantitative Cell-Based Bioassays for Individual or Combination Immune Checkpoint Immunotherapy
Jamison Grailer, Pete Stecha, Julia Gilden, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng

Quantitative Cell-Based Bioassays for Immunotherapy Programs Targeting Immune Checkpoint Co-Stimulatory Receptors
Jun Wang, Michael Beck, Jamison Grailer, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng

Fc Effector Bioassays for Rapid and Quantitative Measurement of ADCC and ADCP Mechanisms of Action
Zhi-jie Jey Cheng, Rich Moravec, Aileen Paguio, Denise Garvin, Frank Fan, and Mei Cong

Pyroptosis Detection via Multiplexing Cell Death and Bioluminescent Caspase-1 Activity Assessments
Martha O’Brien1, Mike Scurria2, Tim Ugo2, Laurent Bernad2, James Cali1, and Dan Lazar1